1-5 of 5
Klaus Martin Kortuem
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2

Yuan Xiao Zhu, Hongwei Yin, Laura A. Bruins, Chang-Xin Shi, Patrick Jedlowski, Meraj Aziz, Chris Sereduk, Klaus Martin Kortuem, Jessica E. Schmidt, Mia Champion, Esteban Braggio, A. Keith Stewart
Journal: Blood
Blood (2015) 125 (3): 483–491.
https://doi.org/10.1182/blood-2014-05-577130
Published: 2015
Includes: Supplemental data
Journal Articles

Cereblon Binding IMiD Small Molecules Mediate Myeloma Cell Death Via IRF4

Yuan Xiao Zhu, Ph.D., Chang-Xin Shi, Ph.D., Laura Bruins, Klaus Martin Kortuem, MD, Jessica Schmidt, Xiu-Bao Chang, Ph.D., Esteban Braggio, Ph.D., Leif Bergsagel, M.D., Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 1807.
https://doi.org/10.1182/blood.V120.21.1807.1807
Published: 2012
Journal Articles

Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma

Steven R. Schuster, MD, Klaus Martin Kortuem, MD, Yuan Xiao Zhu, PhD, Esteban Braggio, Ph.D., Chang-Xin Shi, PhD, Laura Bruins, Jessica Schmidt, Gregory Ahmann, BS, Shaji K. Kumar, MD, S. Vincent Rajkumar, Joseph R. Mikhael, MD, Vivek Roy, M.D., Betsy R. LaPlant, Kristina Laumann, Bart Barlogie, MD, John D Shaughnessy, Jr., PhD, Rafael Fonseca, MD, Leif Bergsagel, MD, Martha Q Lacy, MD, Keith Stewart, MD
Journal: Blood
Blood (2012) 120 (21): 194.
https://doi.org/10.1182/blood.V120.21.194.194
Published: 2012
Journal Articles

The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways

Jan Egan, PhD, Klaus Martin Kortuem, MD, Chang-Xin Shi, PhD, Jessica Schmidt, David Craig, PhD, John Carpten, PhD, Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 3968.
https://doi.org/10.1182/blood.V120.21.3968.3968
Published: 2012
Journal Articles

Activity of Single Agent Drugs in Phase I and II Trials Best Predicts Future Clinical Utility in Multiple Myeloma

Klaus Martin Kortuem, MD, Steven R Schuster, MD, Meaghan L. Khan, MD, Kaitlyn E. Zidich, Victor H Jimenez-Zepeda, MD, Rafael Fonseca, MD, Keith Stewart, MBA, MB, CHB
Journal: Blood
Blood (2012) 120 (21): 4034.
https://doi.org/10.1182/blood.V120.21.4034.4034
Published: 2012